You are here: Industry Insights > Takeda

News List

Takeda Pharmaceuticals Names Emerging Markets President contractpharma
March 31, 2017
Ricardo Marek has been appointed president of Takeda Pharmaceuticals Emerging Markets Business Unit (EM BU).
Takeda off-loads some drug development to JV biospectrumasia
March 17, 2017
The joint venture has already been established within the premises of Takeda's Shonan Research Center in Kanagawa Prefecture
CMO Bushu and Takeda Form Partnership contractpharma
March 03, 2017
Bushu to develop and manufacture Takeda’s clinical trial materials
Takeda completes acquisition of ARIAD Pharmaceuticals biospectrumasia
February 22, 2017
This acquisition will significantly enhances Takeda’s global oncology portfolio
Takeda Completes Acquisition of ARIAD Pharmaceuticals americanpharmaceuticalreview
February 20, 2017
Takeda Pharmaceutical Company has announced the completion of its acquisition of ARIAD Pharmaceuticals, Inc. for $24.00 per share in cash.
Japan’s Takeda acquires US cancer drug manufacturer ARIAD for $5.2bn pharmaceutical-technology
February 20, 2017
Japan-based Takeda Pharmaceutical Company has completed the previously announced acquisition of American oncology company ARIAD Pharmaceuticals for $5.2bn.
PRA Health Sciences and Takeda Partnership Expands to Japan firstwordpharma
February 16, 2017
PRA Health Sciences and Takeda Pharmaceutical Company Limited （TSE: 4502, "Takeda"） announced today that they have agreed to a new partnership to expand their global relationship initially disclosed in September 2016 to include Japan.
Maverick Therapeutics and Takeda Announce Five-Year Collaboration to Advance T-Cell Engagement Thera americanpharmaceuticalreview
January 13, 2017
Maverick Therapeutics Inc. and Takeda Pharmaceutical Company have entered a collaboration to develop Maverick’s T-cell engagement platform created specifically to improve the utility of T-cell redirection therapy for the treatment of cancer. The $125 mill
Japan’s Takeda to acquire US cancer drug manufacturer ARIAD for $5.2bn pharmaceutical-technology
January 11, 2017
Japanese-based Takeda Pharmaceutical Company has signed an agreement to acquire American oncology company ARIAD Pharmaceuticals for approximately $5.2bn.
Takeda to Acquire ARIAD Pharmaceuticals americanpharmaceuticalreview
January 11, 2017
Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 bill

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page